Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SF 1126

Drug Profile

SF 1126

Alternative Names: SF1126

Latest Information Update: 28 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Semafore Pharmaceuticals
  • Developer New Approaches to Neuroblastoma Therapy Consortium; SignalRx Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I Liver cancer
  • No development reported Lymphoproliferative disorders; Multiple myeloma; Neuroblastoma; Solid tumours

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in Canada (IV)
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in USA (IV)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top